Beurs.nl monitor iconMarkt Monitor
  • AEX -7,22 907,46 -0,79%
  • DE40 0,00 22.678,74 0,00%
  • US500^ -130,52 5.563,06 -2,29%
  • US30^ -848,80 41.465,70 -2,01%
  • EUR/USD +0,00 1,0833 +0,34%
  • WTI -0,89 69,05 -1,27%
  • Gold spot +30,68 3.085,69 +1,00%

Amerikaanse aandelen Terug naar discussie overzicht

Amyris

244 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 13 »» | Laatste | Omlaag ↓
  1. nobahamas 29 november 2016 20:32
    Bij 0,83 ben ik weer koper, maar een nieuwe emissie vóór die tijd lijkt me niet geheel onwaarschijnlijk.
  2. forum rang 4 nb 1 december 2016 16:11
    Zeg veer62, je lijkt op profitmaker. Hij spreekt ook in de 3e persoon enkelvoud
  3. veer62 1 december 2016 17:00
    quote:

    nb schreef op 1 december 2016 16:11:

    Zeg veer62, je lijkt op profitmaker. Hij spreekt ook in de 3e persoon enkelvoud
    veer is veer , ben ik nu een slecht mens of zo? Laat mensen gewoon in hun waarde , groetjes veer
  4. nobahamas 1 december 2016 20:46
    quote:

    nb schreef op 1 december 2016 16:10:

    je bent er bijna, Nobahamas
    klopt, maar ik zie nog geen bodem.
    GE ziet er beter uit op dit moment..
  5. [verwijderd] 2 december 2016 14:49
    En alweer een mooi Amyris-bericht (van gisteren 1 dec , maar was hier nog niet geplaatst):

    Amyris Signs Multi-Year Collaboration Extension with Kuraray
    Thu December 1, 2016 8:30 AM|GlobeNewswire|About: AMRS
    GlobeNewswire
    EMERYVILLE, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it has executed with its long-time partner Kuraray Co., LTD (TYO:3405) a multi-year extension to their collaboration agreement for the use of Amyris’s Biofene® branded ß-Farnesene in liquid farnesene rubber (“LFR”) and farnesene-based elastomer applications. This collaboration, which originally began in 2011, features increased farnesene supply to Kuraray and joint marketing of products to industry and end-customers.

    Amyris’s sugar cane-derived Biofene forms the basis for a wide range of products varying from specialty products such as cosmetics, perfumes, detergents and industrial lubricants, to transportation fuels such as diesel and jet fuel. As a tailor made pure hydrocarbon it provides numerous advantages when compared to petroleum-based oils and chemicals and is renewable, contributing to a sustainable future.

    Farnesene Fueling Better Products Across the World – Including Tires

    Kuraray’s recent technological successes with rubber containing farnesene includes an enhanced synthetic additive for tire manufacturers. Its novel LFR and other farnesene- containing rubber materials add substantial grip and cornering capability to tires, particularly in cold, snow and ice conditions. In addition, its hydrogenated styrenic-farnesene copolymer (“HSFC”) has demonstrated superior shock absorption in products ranging from footwear to specialty construction materials.

    “We are delighted to extend our relationship with Kuraray,” said John Melo, CEO of Amyris. “Introducing a novel molecule to industry requires patience and creativity. However, Kuraray’s technical expertise and customer relationships have reached the point where their products are now becoming mainstream and this, in turn, is fueling further broadening market adoption of our farnesene for a variety of products.”

    “Kuraray has many years’ experience working with farnesene, which we believe has many end-market applications,” said Mr. Kenichi Abe, President of Kuraray’s Isoprene business. “Our collaboration with Amyris and their breakthrough-ability to produce farnesene at industrial scale, and at competitive price, enables Kuraray to provide its customers products with superior performance and that are renewably sourced.”
  6. nobahamas 13 december 2016 15:34
    Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced it has signed a definitive agreement to establish a cosmetic ingredients joint venture with NIKKOL GROUP ('NIKKOL'), a leading Japanese cosmetic specialty chemical provider. NIKKOL is purchasing 50% of the Amyris Neossance business for up to $20 million in total. Amyris will receive $10 million of the purchase price upfront and the remaining $10 million is structured as an earn out over the first three years of the joint venture operation.
    www.twst.com/update/amyris-inc-amyris...
  7. nobahamas 14 december 2016 16:19
    Chevron Products Company, a division of Chevron U.S.A. Inc., and Novvi LLC today announced that Chevron has made an equity investment into Novvi LLC (a joint venture of Amyris, Inc. (Nasdaq:AMRS), Cosan S.A., and American Refining Group (ARG)). Terms of the transaction were not disclosed.
    globenewswire.com/news-release/2016/1...
  8. [verwijderd] 16 december 2016 21:12
    Mogelijk ten overvloede, maar misschien nuttig Amyris geinteresseerden te attenderen op een SA draadje, waar nog steeds (ook vandaag) commentaar aan toegevoegd wordt:

    seekingalpha.com/article/4029506-amyr...

    Niet heel veel nieuws maar wellicht nuttig te lezen wat bijvoorbeeld de twijfels van enkele Amerikaanse beleggers zijn (hoge schuld, onvoldoende productiecapaciteit, de nog steeds doorgaande verkoop van Amyris aandelen door een grootaandeelhouder etc.
  9. [verwijderd] 4 januari 2017 12:04
    Ja, Singular Research (wat ik als een zeer gedegen partij beschouw) is heel positief, da's mooi maar belangrijk is ook een van de reacties op dit artikel. Ene Apdamico stelt de volgende vraag aan Singular Research:

    Could you please explain John Melo's comments, during a December 2016 conference, in which he stated that because of the derivative effect, earnings are inversely affected by higher stock prices?
    That comment, which I do not understand, the production being at capacity (with no immediate resolution) and the companies' balance sheet seem to be holding the stock price down.
    Appreciate any color you may be able to provide concerning the derivative effect.
    Thank you for your article and positive outlook!


    Nog geen antwoord van Singular Research op deze zinvolle vraag (kan me voorstellen dat daar wat extra speurwerk voor nodig is), maar ik vind dat zelf wel relevant voor een verdere 'de-risking' van het aandeel Amyris. Mijn advies is dit toch goed in de gaten te houden (kan dus via de hierboven gegeven link).
  10. nobahamas 5 januari 2017 22:51
    Ik zou me er niet teveel op richten.
    Derrivaten dekken een risico af, en dat kost wat. Uitwijden wat er op dit moment afgedekt is, en hoe, krijg je toch niet te horen.
    De omzet neemt toe, en de koers idem.
    Lekker blijven zitten.
244 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 13 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.119
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.173
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.857
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.839
Aedifica 3 926
Aegon 3.258 323.075
AFC Ajax 538 7.089
Affimed NV 2 6.305
ageas 5.844 109.905
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.290
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.276
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 420
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.905
AMG 971 134.353
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.056
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.806
Arcelor Mittal 2.034 320.985
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.352
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.614
ASML 1.766 110.161
ASR Nederland 21 4.512
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.937
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449